Stage I/Smoldering Myeloma Multiple Myeloma

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (02-3-2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were published in The Lancet Oncology, and presented at... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (12-31-2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma (12-8-2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly diagnosed multiple myeloma, according to the results... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (03-7-2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results of a study published in The Lancet Oncology. Multiple... Continue Reading

Early Treatment of Multiple Myeloma Slows Progression (08-30-2013)

Early treatment with Revlimid® (lenalidomide) and dexamethasone for patients with high-risk smoldering multiple myeloma delays progression to active disease and increases overall survival, according to the results of a study published in the New England... Continue Reading

Carfilzomib Promising in Newly Diagnosed Multiple Myeloma (03-13-2012)

The investigational drug carfilzomib, in combination with Revlimid® (lenalidomide) and low-dose dexamethasone, produced high response rates in patients with newly diagnosed myeloma. The results of this Phase I/II clinical trial were presented at the... Continue Reading

Continuous Revlimid May Improve Outcomes in Newly Diagnosed Multiple Myeloma (12-15-2010)

Among older patients with newly diagnosed multiple myeloma, treatment with Revlimid® (lenalidomide) in combination with melphalan and prednisone, followed by Revlimid maintenance therapy (MPR-R) may result in better progression-free survival than two... Continue Reading

Revlimid Maintenance Slows Myeloma Progression After Stem Cell Transplant (12-14-2010)

Maintenance therapy with Revlimid® (lenalidomide) reduced the risk of myeloma progression or death by 60% among patients who had undergone an autologous stem cell transplant. These updated results from a Phase III clinical trial were presented at the... Continue Reading

Improved Survival with Zometa in Multiple Myeloma (12-14-2010)

It appears that treatment of patients with newly diagnosed multiple myeloma with Zometa® (zoledronic acid) may improve overall survival and progression-free survival. These findings were recently reported in The Lancet. Multiple myeloma is a cancer of... Continue Reading

Combination of Velcade and Revlimid Promising Against Newly Diagnosed Multiple Myeloma (10-29-2010)

Among patients with symptomatic newly diagnosed multiple myeloma, treatment with a combination of Revlimid® (lenalidomide), Velcade® (bortezomib), and dexamethasone produced a partial response or better in 100% of patients. The results of this Phase... Continue Reading

Next Page »